Neuraxis, INC (NRXS) Financial Statements
Industry: Electromedical & Electrotherapeutic Apparatus
In fiscal 2025, Neuraxis reported revenue of $3.6M, up 32.9% from $2.7M the year before. Net income was -$7.8M (a -218.5% net margin), or -$0.95 per diluted share. Gross margin was 84.2% and operating margin was -219.4%. Operating activities generated -$6.4M of cash, leaving -$6.5M of free cash flow. At fiscal year end, Neuraxis held $6.4M in total assets against $3.0M in total liabilities, including $5.0M of cash and equivalents.
Open the full interactive Neuraxis financials → Quarterly statements, key ratios, valuation history and price charts.
Neuraxis Key Stats
| Share Price | $6.50 |
|---|---|
| Market Cap | $78.8M |
| Revenue YoY Growth | +32.9% |
| 52-Week Range | $2.31 – $8.81 |
| Shares Outstanding | 12.1 million (basic, 2026 Q2) |
Neuraxis Income Statement
| FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|
| Revenue | $2.5M | $2.7M | $3.6M |
| Cost of Goods Sold | $303,345 | $362,002 | $562,916 |
| Gross Profit | $2.2M | $2.3M | $3.0M |
| Operating Income | -$6.7M | -$7.2M | -$7.8M |
| Pre-Tax Income | -$14.6M | -$8.2M | -$7.8M |
| Net Income | -$14.6M | -$8.2M | -$7.8M |
| Diluted EPS | -$4.50 | -$1.22 | -$0.95 |
Neuraxis Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $811,414 | $968,127 | $1.6M | $1.9M |
| Net Income | -$2.1M | -$1.7M | -$1.8M | -$2.1M |
| Diluted EPS | -$0.24 | -$0.19 | -$0.18 | -$0.19 |
Neuraxis Balance Sheet
| FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|
| Cash & Equivalents | $78,560 | $3.7M | $5.0M |
| Current Assets | $242,610 | $4.3M | $5.7M |
| Total Assets | $509,498 | $4.8M | $6.4M |
| Current Liabilities | $1.9M | $2.4M | $2.8M |
| Total Liabilities | $1.9M | $2.7M | $3.0M |
| Shareholders' Equity | -$1.4M | $2.1M | $3.4M |
Neuraxis Cash Flow Statement
| FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|
| Cash From Operations | -$6.7M | -$6.1M | -$6.4M |
| Cash From Investing | -$71,781 | -$27,776 | -$131,150 |
| Cash From Financing | $6.6M | $9.7M | $7.8M |
| Free Cash Flow | -$6.7M | -$6.1M | -$6.5M |
Figures from Neuraxis' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Neuraxis financials page for every line item.
Neuraxis Company Profile
| Ticker | NRXS |
|---|---|
| Exchange | NYSE |
| Industry | Electromedical & Electrotherapeutic Apparatus |
| Headquarters | Carmel, Indiana |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0001933567 |
Frequently Asked Questions
What was Neuraxis' revenue in fiscal 2025?
Neuraxis (NRXS) reported revenue of $3.6M for fiscal 2025.
What is Neuraxis' annual revenue history?
Neuraxis' annual revenue by fiscal year: 2023: $2.5M; 2024: $2.7M; 2025: $3.6M.
What was Neuraxis' net income in fiscal 2025?
Neuraxis reported net income of -$7.8M for fiscal 2025.
What was Neuraxis' earnings per share (EPS) in fiscal 2025?
Neuraxis' diluted EPS was -$0.95 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Neuraxis generate in fiscal 2025?
Neuraxis generated -$6.5M of free cash flow in fiscal 2025.
What was Neuraxis' revenue last quarter?
In its most recent reported quarter (2026 Q2), Neuraxis reported revenue of $1.9M.
How many shares of Neuraxis are outstanding?
Neuraxis reported a weighted average of 12.1 million basic shares outstanding in 2026 Q2.
What is Neuraxis' market cap?
Based on its latest closing price, Neuraxis (NRXS) has a market capitalization of about $78.8M.
When does Neuraxis' fiscal year end?
Neuraxis' fiscal year end, as registered with the SEC, is December 31.
Where is Neuraxis headquartered?
Neuraxis lists its business address in Carmel, Indiana in its SEC filings.